中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

104 records (took 0.021 seconds)

    INJECTABLE NANO-NETWORK GELS FOR DIABETES TREATMENT
    52.
    发明申请
    INJECTABLE NANO-NETWORK GELS FOR DIABETES TREATMENT 审中-公开
    注射用于糖尿病治疗的纳米网络凝胶

    公开(公告)号：US20160067190A1

    公开(公告)日：2016-03-10

    申请号：US14787652

    申请日：2014-04-29

    Applicant: THE CHILDREN'S MEDICAL CENTER CORPORATION ,  MASSACHUSETTS INSTITUTE OF TECHNOLOGY

    Inventor： Daniel G. Anderson ,  Zhen Gu ,  Alex Arthur Aimetti ,  Robert S. Langer

    IPC: A61K9/51 ,  A61K38/44 ,  A61K9/00 ,  A61K38/28

    CPC classification number: A61K9/5161 ,  A61K9/0019 ,  A61K38/28 ,  A61K38/443 ,  A61K47/36 ,  B82Y5/00 ,  B82Y40/00

    Abstract: A system for “smart” delivery of a therapeutic, prophylactic or diagnostic agent, such as glucose-mediated delivery of insulin through an injectable nano-network consisting of oppositely-charged dextran nanoparticles encapsulating insulin and glucose-specific enzymes forming a gel-like 3D scaffold. As demonstrated by the examples, the system effectively dissociates to release insulin in a hyperglycemic condition, where the catalytic conversion of glucose into gluconic acid and the subsequent degradation of polymeric matrix are facilitated. This formulation design provides a delivery strategy for both self-regulated and long-term diabetes management.

    Abstract translation: 用于“智能”递送治疗性，预防性或诊断性药物的系统，例如葡萄糖介导的胰岛素递送通过由包含胰岛素的葡萄糖纳米微粒组成的可注射纳米网络和形成凝胶状3D的葡萄糖特异性酶 脚手架。 如实施例所证明的，系统有效地解离以在高血糖状态释放胰岛素，其中促进葡萄糖转化为葡萄糖酸并随后降解聚合物基质。 该配方设计提供了自我调节和长期糖尿病管理的交付策略。

    GLUCOSE-RESPONSIVE MICROGELS FOR CLOSED LOOP INSULIN DELIVERY
    53.
    发明申请
    GLUCOSE-RESPONSIVE MICROGELS FOR CLOSED LOOP INSULIN DELIVERY 有权
    用于闭合环路胰岛素递送的葡萄糖反应性微胶囊

    公开(公告)号：US20150030641A1

    公开(公告)日：2015-01-29

    申请号：US14379481

    申请日：2013-02-19

    Applicant: Massachusetts Institute of Technology

    Inventor： Daniel G. Anderson ,  Zhen Gu ,  Robert S. Langer

    IPC: A61K38/28 ,  A61K9/51 ,  A61K9/00 ,  A61K38/44

    CPC classification number: A61K38/28 ,  A61K9/0019 ,  A61K9/5026 ,  A61K9/5031 ,  A61K9/5036 ,  A61K9/5138 ,  A61K9/5161 ,  A61K38/44 ,  A61K38/443 ,  C12Y101/03004 ,  C12Y111/01006 ,  A61K2300/00

    Abstract: Injectable insulin loaded microgels that are capable of modifying the amount of insulin released based on the patient's tissue glucose levels, methods for making and using these compositions have been developed. The microgels contain insulin, glucose oxidase entrapped in or bound to the microgels, and an agent that reduces hydrogen peroxide, entrapped in or bound to the microgels, wherein the polymeric microgel expands when pH decreases from physiological pH and shrinks when pH increases towards physiological pH, thereby releasing insulin at a rate corresponding to the glucose concentration. In one embodiment, the glucose oxidase and/or the agent reducing hydrogen peroxide are encapsulated in nanogels, then encapsulated within the microgel.

    Abstract translation: 已经开发了能够改变基于患者组织葡萄糖水平释放的胰岛素量的可注射胰岛素负载微凝胶，制备和使用这些组合物的方法。 微凝胶含有胰岛素，包裹在微凝胶中或与微凝胶结合的葡萄糖氧化酶，以及减少过氧化氢，夹带或结合到微凝胶上的试剂，其中当pH从生理pH降低时，聚合物微凝胶膨胀，并且当pH向生理pH增加时收缩 从而以对应于葡萄糖浓度的速度释放胰岛素。 在一个实施方案中，葡萄糖氧化酶和/或还原过氧化氢的试剂被包封在纳米凝胶中，然后封装在微凝胶内。

    MICRONEEDLE DEVICES AND USES THEREOF
    54.
    发明申请
    MICRONEEDLE DEVICES AND USES THEREOF 审中-公开
    MICRONEEDLE设备及其用途

    公开(公告)号：US20130165772A1

    公开(公告)日：2013-06-27

    申请号：US13728300

    申请日：2012-12-27

    Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGY ,  THE GENERAL HOSPITAL CORPORATION

    Inventor： Carlo Giovanni Traverso ,  Avraham D. Schroeder ,  Baris Erinc Polat ,  Carl Magnus Schoellhammer ,  Daniel Blankschtein ,  Daniel G. Anderson ,  Robert S. Langer

    IPC: A61M37/00 ,  A61M5/00

    Abstract: The present disclosure provides devices and uses thereof A devices disclosed herein comprises a plurality of microneedles adapted to protrude from the device. In some embodiments, a device is dimensioned and constructed to carry a payload, so that the payload can be delivered to an internal tissue of a subject or through a wall of a vessel after interaction with microneedles. In some embodiments, devices can be used for oral or intravenous administration. In some embodiments, devices can be used for implantation such as vaginal, rectal, urethral or bladder suppository or pessary.

    Abstract translation: 本公开提供了装置及其用途。本文公开的装置包括适于从装置突出的多个微针。 在一些实施例中，将装置的尺寸设计和构造为承载有效载荷，使得有效载荷可以在与微针相互作用之后被递送到受试者的内部组织或通过血管的壁。 在一些实施方案中，装置可用于口服或静脉内施用。 在一些实施例中，装置可用于植入，例如阴道，直肠，尿道或膀胱栓剂或子宫托。

    Circular RNA for translation in eukaryotic cells
    58.
    发明授权
    Circular RNA for translation in eukaryotic cells 有权

    公开(公告)号：US11352641B2

    公开(公告)日：2022-06-07

    申请号：US17468100

    申请日：2021-09-07

    Applicant: Massachusetts Institute of Technology

    Inventor： Daniel G. Anderson ,  Robert Alexander Wesselhoeft ,  Piotr S. Kowalski

    IPC: A61K48/00 ,  C12N15/63 ,  C12N15/79 ,  C07H21/04 ,  C12N15/85 ,  C07K16/28 ,  C12N15/11

    Abstract: Methods and constructs for engineering circular RNA are disclosed. In some embodiments, the methods and constructs comprise a vector for making circular RNA, the vector comprising the following elements operably connected to each other and arranged in the following sequence: a.) a 5′ homology arm, b.) a 3′ group I intron fragment containing a 3′ splice site dinucleotide, c.) optionally, a 5′ spacer sequence, d.) a protein coding or noncoding region, e.) optionally, a 3′ spacer sequence, f) a 5′ Group I intron fragment containing a 5′ splice site dinucleotide, and g.) a 3′ homology arm, the vector allowing production of a circular RNA that is translatable or biologically active inside eukaryotic cells. Methods for purifying the circular RNA produced by the vector and the use of nucleoside modifications in circular RNA produced by the vector are also disclosed.

    Circular RNA for translation in eukaryotic cells
    59.
    发明授权
    Circular RNA for translation in eukaryotic cells 有权

    公开(公告)号：US11352640B2

    公开(公告)日：2022-06-07

    申请号：US17374497

    申请日：2021-07-13

    Applicant: Massachusetts Institute of Technology

    Inventor： Daniel G. Anderson ,  Robert Alexander Wesselhoeft ,  Piotr S. Kowalski

    IPC: A61K48/00 ,  C12N15/63 ,  C12N15/79 ,  C07H21/04 ,  C12N15/85 ,  C07K16/28 ,  C12N15/11

    Abstract: Methods and constructs for engineering circular RNA are disclosed. In some embodiments, the methods and constructs comprise a vector for making circular RNA, the vector comprising the following elements operably connected to each other and arranged in the following sequence: a.) a 5′ homology arm, b.) a 3′ group I intron fragment containing a 3′ splice site dinucleotide, c.) optionally, a 5′ spacer sequence, d.) a protein coding or noncoding region, e.) optionally, a 3′ spacer sequence, f.) a 5′ Group I intron fragment containing a 5′ splice site dinucleotide, and g.) a 3′ homology arm, the vector allowing production of a circular RNA that is translatable or biologically active inside eukaryotic cells. Methods for purifying the circular RNA produced by the vector and the use of nucleoside modifications in circular RNA produced by the vector are also disclosed.

Patent Agency Ranking